Caramés Masana Francisco, de Reijke Theo M
a Department of Urology , Complexo Hospitalario Universitario de A Coruña , A Coruña , Spain.
b Academic Medical Center , Amsterdam , the Netherlands.
Expert Opin Pharmacother. 2017 Nov;18(16):1781-1788. doi: 10.1080/14656566.2017.1392510. Epub 2017 Oct 20.
Bladder cancer is nowadays a common tumor. Non-muscle invasive bladder cancer (NMIBC) has still chances of recurrence and progression in spite of surgery and adjuvant treatments. New therapies are being developed to reduce these percentages with less adverse effects - Apaziquone (EO9) is an example. Areas covered: A literature search has been performed using Pubmed, UpToDate and Google verified information (mainly from Food and Drug Administration and Spectrum Pharmaceutics websites). We have included data from the most representative clinical trials and reviews published. Expert opinion: Apaziquone is considered a promising chemical agent if applied intravesically due mainly to its pharmacodynamics and safety profile. There is evidence for this with respect to adjuvant chemo ablative therapy and as a post-transurethral resection of bladder (TURB) single-dose regimen. As a result, new clinical phase III trials are needed both to evaluate its efficacy as an adjuvant therapy in the spectrum from intermediate- to high-risk non-muscle invasive bladder cancer and to select the most appropriate candidates and treatment schedule. As a conclusion, Apaziquone is a good candidate to become a better alternative as an adjuvant therapy for the treatment of NMIBC in the near future.
膀胱癌如今是一种常见肿瘤。尽管进行了手术及辅助治疗，非肌层浸润性膀胱癌（NMIBC）仍有复发和进展的可能。正在研发新的疗法以降低这些比例且减少不良反应——阿帕喹酮（EO9）就是一个例子。涵盖领域：使用PubMed、UpToDate以及经谷歌验证的信息（主要来自美国食品药品监督管理局和Spectrum制药公司网站）进行了文献检索。我们纳入了已发表的最具代表性的临床试验和综述数据。专家观点：阿帕喹酮若经膀胱内给药，主要因其药效学和安全性特征，被认为是一种有前景的化学药剂。在辅助化学消融治疗以及作为经尿道膀胱肿瘤切除术（TURB）单剂量方案方面有相关证据支持。因此，需要开展新的III期临床试验，以评估其作为中高危非肌层浸润性膀胱癌辅助治疗的疗效，并选择最合适的候选患者和治疗方案。总之，阿帕喹酮很有可能在不久的将来成为治疗NMIBC更好的辅助治疗选择。
